Bubs secures permanent FDA authorisation for US infant formula supply
Bubs Australia (ASX:BUB) has received permanent regulatory authorisation from the United States Food and Drug Administration (FDA) for three of its infant formula products. The approval covers Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential.
The authorisation provides a permanent pathway to supply what the company describes as “one of the world’s largest infant formula markets.” This converts prior access into a durable competitive position, building on a US presence where Bubs is already represented in more than 10,000 stores nationwide.
When big ASX news breaks, our subscribers know first
What permanent FDA authorisation actually means
The approval confirms that Bubs’ products, manufacturing systems and scientific evidence satisfy US regulatory requirements. Key facts from the announcement include:
-
Permanent FDA authorisation secured for all three named products
-
Confirmation that products, manufacturing systems and scientific evidence meet US requirements for safety, nutritional adequacy and quality
-
Positioning as the only Australian infant formula brand, and one of a limited number of international manufacturers, able to supply the US market
The company frames the outcome as membership within a limited group of non-US manufacturers authorised to participate in the market, an angle that speaks directly to competitive positioning.
Why the US infant formula market is so hard to enter
The United States infant formula market is described in the announcement as one of the most highly regulated consumer categories globally, with substantial scientific, regulatory and manufacturing requirements for entry.
These requirements create a high barrier that few international manufacturers clear. For investors, that barrier matters. High entry thresholds tend to protect those already inside the market, meaning permanent authorisation functions as a strategic asset that is not easily replicated by competitors.
Rather than a temporary or conditional pathway, the permanent status establishes a foundation for continued growth across Bubs’ branded portfolio while creating optionality for future product innovation and market expansion.
What this unlocks for Bubs’ US growth strategy
The approval provides a platform for the company to accelerate its US growth strategy. According to management, the authorisation supports deeper retailer partnerships, stronger consumer awareness of the Bubs brand and expanded consumer reach across a market where the company already operates in more than 10,000 stores nationwide.
The announcement also states that the approval creates additional opportunities to broaden the product offering and to “evaluate participation in the US private label infant nutrition segment.” This remains an option rather than a committed plan.
FY26 US revenue growth reached 24% to $65.8M as the distribution network expanded from 4,000 to more than 10,000 stores, though a gross margin shortfall attributed to air freight, regulatory reset costs and US tariffs kept reported EBITDA in negative territory for the full year.
Bubs notes that any private label expansion “remains subject to further regulatory, technical and commercial milestones.” Investors should treat this as potential upside rather than a confirmed revenue stream.
| Development | What the source states | Status | Investor implication |
|---|---|---|---|
| Permanent FDA authorisation | Secured for 3 products | Confirmed | Durable market access |
| US retail footprint | 10,000+ stores | Confirmed | Existing distribution base |
| Private label segment | Evaluating participation | Optionality — subject to milestones | Potential upside, not guaranteed |
Management perspective
Joe Coote, Managing Director and CEO of Bubs, framed the outcome as a defining moment for the company’s US ambitions.
Joe Coote, Managing Director and CEO
“Permanent FDA authorisation is a transformational milestone for Bubs and validates the strength of our farm-to-formula value chain, manufacturing capability and product quality. This approval provides the platform to accelerate our US growth strategy, deepen retailer partnerships, strengthen consumer awareness of the Bubs brand and expand consumer reach across a market where we are already represented in more than 10,000 stores nationwide.”
What’s next: investor webinar and timeline
Bubs will host an investor webinar to discuss the FDA authorisation and its US growth strategy. Key details include:
-
Investor webinar scheduled for Thursday, 10 September 2026
-
Topic: the FDA authorisation and the company’s US growth strategy
-
Registration details to be provided separately and made available via the ASX and the Bubs Investor Centre
The webinar gives shareholders a defined date to hear management set out the growth roadmap in greater detail.
Don’t Miss the Next Consumer Sector Breakthrough
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.